← All drugs
Drug · FAERS side-effect profile with label screen

Fluoxetine Hydrochloride side effects: what 126,801 FDA adverse event reports show

Fluoxetine Hydrochloride · 1,184 reaction terms · 512,787 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

126,801 reports · 72% serious · 12,911 with death outcome · 72% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Fluoxetine capsules are indicated for the treatment of: • Acute and maintenance treatment of Major Depressive Disorder [ see Clinical Studies (14.1)]. • Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [ see Clinical Studies (14.2 )].

FDA label, Indications and Usage

What it is

N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine is an aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

PubChem CID 3386 (ChEBI)

Boxed warning

SUICIDAL THOUGHTS AND BEHAVIORS • Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the r.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 1Labeled adverse reaction 5Labeled (related wording) 3Likely indication confounding 4Reporting / coding artifact 2Lab value / disease marker 4Not in label — unassessed 21
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,144 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Antidepressant drug level increased9156.5
44.5–71.8ROR 56.6 · calibrated p 8e-6 ✓
41.8 EB05 35.1 · IC025 +4.8
3/3 methods agree
Lab value / disease markerserious n=91 · ♀ 0% (drug 72%) · 100% cliniciannot reported in cached trials
Antipsychotic drug level below therapeutic17254.3
45.7–64.5ROR 54.3 · calibrated p 9e-6 ✓
40.7 EB05 35.9 · IC025 +4.9
3/3 methods agree
Lab value / disease markerserious n=169 · ♀ 0% (drug 72%) · 100% cliniciannot reported in cached trials
Amaurosis fugax22944.9
38.8–52.0ROR 45.0 · calibrated p 3e-5 ✓
35.3 EB05 31.6 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious n=229 · 100% cliniciannot reported in cached trials
Persistent foetal circulation9228.8
23.1–35.9ROR 28.8 · calibrated p 4e-4 ✓
24.5 EB05 20.6 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=92 · 100% cliniciannot reported in cached trials
Disinhibition22626.8
23.3–30.9ROR 26.9 · calibrated p 5e-4 ✓
23.1 EB05 20.7 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=223 · ♀ 0% (drug 72%)not reported in cached trials
Serotonin syndrome2,36423.2
22.2–24.2ROR 23.6 · calibrated p 9e-4 ✓
20.4 EB05 19.7 · IC025 +4.3
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 16.4 · serious PRR 16.5not reported in cached trials
Physical deconditioning29221.7
19.2–24.5ROR 21.8 · calibrated p 0.001 ✓
19.3 EB05 17.5 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=292not reported in cached trials
Autism11821.3
17.6–25.8ROR 21.3 · calibrated p 0.002 ✓
18.9 EB05 16.2 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=116 · 100% consumernot reported in cached trials
Craniosynostosis9620.4
16.5–25.2ROR 20.4 · calibrated p 0.002 ✓
18.2 EB05 15.3 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=96 · 100% consumernot reported in cached trials
Talipes26515.3
13.5–17.4ROR 15.4 · calibrated p 0.006 ✓
14.1 EB05 12.7 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=265 · ♀ 100% (drug 72%)not reported in cached trials
Bezoar11515.0
12.4–18.1ROR 15.0 · calibrated p 0.008 ✓
13.7 EB05 11.7 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=115 · ♀ 100% (drug 72%) · 100% cliniciannot reported in cached trials
Reversible cerebral vasoconstriction syndrome16214.8
12.6–17.4ROR 14.8 · calibrated p 0.008 ✓
13.6 EB05 11.9 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=162 · ♀ 100% (drug 72%) · 100% cliniciannot reported in cached trials
Binge eating8714.5
11.6–18.1ROR 14.5 · calibrated p 0.009 ✓
13.3 EB05 11.1 · IC025 +3.3
3/3 methods agree
Likely indication confounding
term in indications
serious n=78 · ♀ 100% (drug 72%) · 100% consumernot reported in cached trials
Major depression58414.2
13.1–15.5ROR 14.3 · calibrated p 0.009 ✓
13.2 EB05 12.3 · IC025 +3.6
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
serious PRR 10.7not reported in cached trials
Obsessive-compulsive disorder59513.1
12.0–14.2ROR 13.1 · calibrated p 0.012 ✓
12.2 EB05 11.4 · IC025 +3.5
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=523 · ♀ 36% (drug 72%)not reported in cached trials
Homicide12612.3
10.3–14.8ROR 12.3 · calibrated p 0.016 ✓
11.4 EB05 9.8 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=125 · ♀ 0% (drug 72%)not reported in cached trials
Anorgasmia17811.5
9.9–13.4ROR 11.5 · calibrated p 0.020 ✓
10.7 EB05 9.4 · IC025 +3.1
3/3 methods agree
Labeled adverse reaction
exact term
serious n=145 · 100% consumernot reported in cached trials
Suicidal behaviour26911.3
10.0–12.8ROR 11.3 · calibrated p 0.021 ✓
10.6 EB05 9.5 · IC025 +3.2
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=266not reported in cached trials
Depersonalisation/derealisation disorder9910.8
8.8–13.2ROR 10.8 · calibrated p 0.026 ✓
10.0 EB05 8.4 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=93 · ♀ 0% (drug 72%) · 100% consumernot reported in cached trials
Hyperreflexia21210.6
9.2–12.2ROR 10.6 · calibrated p 0.027 ✓
9.9 EB05 8.8 · IC025 +3.1
3/3 methods agree
Labeled adverse reaction
exact term
serious n=208 · 100% cliniciannot reported in cached trials
Cleft palate11710.6
8.8–12.8ROR 10.6 · calibrated p 0.028 ✓
9.8 EB05 8.4 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=117not reported in cached trials
Antipsychotic drug level increased16910.5
9.0–12.3ROR 10.5 · calibrated p 0.028 ✓
9.8 EB05 8.6 · IC025 +3.0
3/3 methods agree
Lab value / disease markerserious n=166 · ♀ 45% (drug 72%) · 100% cliniciannot reported in cached trials
Clonus16310.4
8.9–12.2ROR 10.4 · calibrated p 0.029 ✓
9.7 EB05 8.5 · IC025 +3.0
3/3 methods agree
Labeled adverse reaction
exact term
serious n=160 · 100% cliniciannot reported in cached trials
Oculogyric crisis1169.6
8.0–11.6ROR 9.6 · calibrated p 0.039 ✓
8.9 EB05 7.6 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=111 · 100% cliniciannot reported in cached trials
Self-injurious ideation2289.5
8.3–10.8ROR 9.5 · calibrated p 0.039 ✓
8.9 EB05 8.0 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=214not reported in cached trials
Intentional self-injury1,0869.4
8.8–9.9ROR 9.4 · calibrated p 0.039 ✓
8.9 EB05 8.4 · IC025 +3.0
3/3 methods agree
Reporting / coding artifactserious PRR 7.2not reported in cached trials
Tearfulness2289.2
8.0–10.5ROR 9.2 · calibrated p 0.044 ✓
8.6 EB05 7.7 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=207not reported in cached trials
Urinary tract disorder2339.0
7.9–10.2ROR 9.0 · calibrated p 0.047 ✓
8.5 EB05 7.6 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=230 · 100% cliniciannot reported in cached trials
Ventricular septal defect2958.9
7.9–10.0ROR 8.9 · calibrated p 0.048 ✓
8.4 EB05 7.6 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=295not reported in cached trials
Derealisation1078.7
7.1–10.5ROR 8.7 · calibrated p 0.054
8.1 EB05 6.8 · IC025 +2.7
3/3 methods agree
Not in label — unassessedserious n=98 · ♀ 0% (drug 72%) · 100% consumernot reported in cached trials
Akathisia (inner restlessness)6828.6
8.0–9.3ROR 8.7 · calibrated p 0.052
8.2 EB05 7.7 · IC025 +2.9
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 8.2 · ♀ 44% (drug 72%)not reported in cached trials
Atrial septal defect4128.5
7.7–9.4ROR 8.5 · calibrated p 0.056
8.1 EB05 7.4 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious PRR 6.5not reported in cached trials
Gambling disorder1338.5
7.1–10.1ROR 8.5 · calibrated p 0.057
7.9 EB05 6.9 · IC025 +2.7
3/3 methods agree
Not in label — unassessedserious n=118 · 100% consumernot reported in cached trials
Intentional overdose3,0598.3
8.0–8.6ROR 8.5 · calibrated p 0.056
7.9 EB05 7.7 · IC025 +2.9
3/3 methods agree
Reporting / coding artifactage-adj. PRR 5.7 · serious PRR 6.6not reported in cached trials
Physical assault1008.3
6.8–10.1ROR 8.3 · calibrated p 0.063
7.7 EB05 6.5 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=94 · ♀ 0% (drug 72%) · 100% consumernot reported in cached trials
Electrocardiogram qrs complex prolonged2438.2
7.2–9.3ROR 8.2 · calibrated p 0.062
7.8 EB05 7.0 · IC025 +2.7
3/3 methods agree
Lab value / disease markerserious n=242 · 100% cliniciannot reported in cached trials
Hostility1228.2
6.8–9.8ROR 8.2 · calibrated p 0.064
7.7 EB05 6.6 · IC025 +2.6
3/3 methods agree
Labeled adverse reaction
exact term
serious n=104not reported in cached trials

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Suicidality10,5147.37.2–7.5signal
Depression7,4114.44.3–4.5signal
Extrapyramidal2,7394.44.2–4.6signal
Hyponatraemia1,3382.82.6–2.9signal
Seizure2,8612.42.3–2.5signal
Arrhythmia / qt2,6302.32.2–2.3signal
Rhabdomyolysis / myopathy9912.01.9–2.2raised
Fall / fracture4,5572.01.9–2.1raised
Pancreatitis8281.71.6–1.8raised
Dependence / withdrawal2,7171.51.5–1.6raised
Kidney injury4,1181.51.5–1.5raised
Hyperglycaemia / diabetes2,9241.41.4–1.5raised
Gi bleeding1,5381.41.3–1.5raised
Venous thromboembolism1,7521.31.3–1.4raised
Hypoglycaemia7531.31.2–1.4raised
Serious infection5,7761.21.2–1.3raised

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Fluoxetine as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug ineffective (drug did not work)8,1571.0
1.0–1.0ROR 1.0 · calibrated p 0.323
1.0 EB05 1.0 · IC025 -0.0
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 1.0 · serious PRR 1.3not reported in cached trials
Nausea7,4641.6
1.5–1.6ROR 1.6 · calibrated p 0.710
1.6 EB05 1.5 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.3 · serious PRR 1.6not reported in cached trials
Headache6,3791.7
1.7–1.7ROR 1.7 · calibrated p 0.786
1.7 EB05 1.6 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.8NCT03466346: 1/160 (0.6%) on Fluoxetine
Depression5,8934.4
4.2–4.5ROR 4.5 · calibrated p 0.294
4.3 EB05 4.2 · IC025 +2.0
3/3 methods agree
Labeled — boxed warning
synonym match
age-adj. PRR 3.6 · serious PRR 3.7not reported in cached trials
Anxiety5,7673.4
3.3–3.5ROR 3.5 · calibrated p 0.483
3.3 EB05 3.3 · IC025 +1.7
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 3.0 · serious PRR 3.1not reported in cached trials
Dizziness5,2221.7
1.7–1.8ROR 1.8 · calibrated p 0.814
1.7 EB05 1.7 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.8NCT03466346: 1/160 (0.6%) on Fluoxetine
Diarrhoea (diarrhea)5,1441.3
1.3–1.4ROR 1.3 · calibrated p 0.534
1.3 EB05 1.3 · IC025 +0.4Labeled adverse reaction
exact term
age-adj. PRR 1.2 · serious PRR 1.2not reported in cached trials
Off label use (used outside approved label)5,1121.0
0.9–1.0ROR 1.0 · calibrated p 0.289
1.0 EB05 1.0 · IC025 -0.1
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.9 · serious PRR 1.0not reported in cached trials
Pain5,0151.4
1.3–1.4ROR 1.4 · calibrated p 0.552
1.3 EB05 1.3 · IC025 +0.4Not in label — unassessedage-adj. PRR 1.3 · serious PRR 1.3NCT03466346: 1/1,082 (0.1%) on Fluoxetine (serious AE)
Drug interaction4,9475.3
5.1–5.4ROR 5.5 · calibrated p 0.190
5.2 EB05 5.0 · IC025 +2.3
3/3 methods agree
Reporting / coding artifactage-adj. PRR 4.7 · serious PRR 4.4not reported in cached trials
Vomiting4,7851.7
1.6–1.7ROR 1.7 · calibrated p 0.783
1.7 EB05 1.6 · IC025 +0.7Likely indication confounding
term in indications; also in warnings
age-adj. PRR 1.4 · serious PRR 1.6not reported in cached trials
Dyspnoea (shortness of breath)4,6911.4
1.3–1.4ROR 1.4 · calibrated p 0.568
1.4 EB05 1.3 · IC025 +0.4Labeled adverse reaction
exact term
age-adj. PRR 1.2 · serious PRR 1.2not reported in cached trials
Fall4,3352.2
2.1–2.2ROR 2.2 · calibrated p 0.945
2.2 EB05 2.1 · IC025 +1.1
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.1 · serious PRR 1.8not reported in cached trials
Toxicity to various agents4,3244.3
4.2–4.5ROR 4.5 · calibrated p 0.301
4.3 EB05 4.2 · IC025 +2.0
3/3 methods agree
Not in label — unassessedage-adj. PRR 3.8 · serious PRR 3.5 · 90% cliniciannot reported in cached trials

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Fluoxetine ↔ Serotonin syndrome.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Fluoxetine?

In FDA FAERS, the most frequently co-reported reaction terms for Fluoxetine are nausea, fatigue, headache, depression, anxiety, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Fluoxetine have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: SUICIDAL THOUGHTS AND BEHAVIORS • Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the r.

Do FAERS signals prove that Fluoxetine causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.